{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T09:01:54Z","timestamp":1771232514817,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["NKI-2016-8210"],"award-info":[{"award-number":["NKI-2016-8210"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["Pink Ribbon 2016-206"],"award-info":[{"award-number":["Pink Ribbon 2016-206"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Dutch Innovation Fund Health insurers","award":["IFZ"],"award-info":[{"award-number":["IFZ"]}]},{"name":"Dutch Innovation Fund Health insurers","award":["project 3.642"],"award-info":[{"award-number":["project 3.642"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Neoadjuvant systemic treatment (NST) leads to pathologic complete response (pCR) in 10\u201389% of breast cancer patients depending on subtype. The added value of surgery is uncertain in patients who reach pCR; however, current imaging and biopsy techniques aiming to predict pCR are not accurate enough. This study aims to quantify the residual disease remaining after NST in patients with a favorable response on MRI and residual disease missed with biopsies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In the MICRA trial, patients with a favorable response to NST on MRI underwent ultrasound-guided post-NST 14G biopsies followed by surgery. We analyzed pathology reports of the biopsies and the surgical specimens. Primary outcome was the extent of residual invasive disease among molecular subtypes, and secondary outcome was the extent of missed residual invasive disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We included 167 patients. Surgical specimen showed residual invasive disease in 69 (41%) patients. The median size of residual invasive disease was 18 mm (interquartile range [IQR] 12\u201330) in hormone receptor-positive (HR+)\/human epidermal growth factor receptor 2-negative (HER2\u2212) patients, 8 mm (IQR 3\u201315) in HR+\/HER2-positive (HER2+) patients, 4\u00a0mm (IQR 2\u20139) in HR-negative (HR\u2212)\/HER2+ patients, and 5 mm (IQR 2\u201311) in triple-negative (TN) patients. Residual invasive disease was missed in all subtypes varying from 4 to 7\u00a0mm.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Although the extent of residual invasive disease is small in TN and HER2+ subtypes, substantial residual invasive disease is left behind in all subtypes with 14G biopsies. This may hamper local control and limits adjuvant systemic treatment options. Therefore, surgical excision remains obligatory until accuracy of imaging and biopsy techniques improve.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1245\/s10434-023-13476-6","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T15:29:53Z","timestamp":1681831793000},"page":"4682-4689","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Biopsy-Guided Pathological Response Assessment in Breast Cancer is Insufficient: Additional Pathology Findings of the MICRA Trial"],"prefix":"10.1245","volume":"30","author":[{"given":"Annemiek K. E.","family":"van Hemert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederieke H.","family":"van Duijnhoven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariane A.","family":"van Loevezijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudette E.","family":"Loo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry","family":"Wiersma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie J.","family":"Groen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Jeanne T. F. D. Vrancken","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,18]]},"reference":[{"issue":"Suppl 3","key":"13476_CR1","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1245\/s10434-018-7046-9","volume":"25","author":"BL Murphy","year":"2018","unstructured":"Murphy BL, Boughey JC. ASO author reflections: changes in Use of neoadjuvant chemotherapy over time-highest rates of use now in triple-negative and HER2+ Disease. Ann Surg Oncol. 2018;25(Suppl 3):695\u20136. https:\/\/doi.org\/10.1245\/s10434-018-7046-9.","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"13476_CR2","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1245\/s10434-010-1008-1","volume":"17","author":"ME Straver","year":"2010","unstructured":"Straver ME, Rutgers EJ, Rodenhuis S, Linn SC, Loo CE, Wesseling J, et al. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol. 2010;17(9):2411\u20138. https:\/\/doi.org\/10.1245\/s10434-010-1008-1.","journal-title":"Ann Surg Oncol"},{"issue":"29","key":"13476_CR3","doi-asserted-by":"publisher","first-page":"3623","DOI":"10.1200\/JCO.2012.45.0940","volume":"31","author":"G von Minckwitz","year":"2013","unstructured":"von Minckwitz G, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Eiermann W, et al. Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2013;31(29):3623\u201330. https:\/\/doi.org\/10.1200\/JCO.2012.45.0940.","journal-title":"J Clin Oncol"},{"issue":"12","key":"13476_CR4","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1200\/JCO.2009.23.8303","volume":"28","author":"G von Minckwitz","year":"2010","unstructured":"von Minckwitz G, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol. 2010;28(12):2015\u201323. https:\/\/doi.org\/10.1200\/JCO.2009.23.8303.","journal-title":"J Clin Oncol"},{"issue":"9","key":"13476_CR5","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","volume":"24","author":"A Schneeweiss","year":"2013","unstructured":"Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278\u201384. https:\/\/doi.org\/10.1093\/annonc\/mdt182.","journal-title":"Ann Oncol"},{"issue":"4","key":"13476_CR6","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa1111065","volume":"366","author":"G von Minckwitz","year":"2012","unstructured":"von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med. 2012;366(4):299\u2013309. https:\/\/doi.org\/10.1056\/NEJMoa1111065.","journal-title":"N Engl J Med"},{"issue":"12","key":"13476_CR7","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1200\/JCO.2009.23.8451","volume":"28","author":"M Untch","year":"2010","unstructured":"Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol. 2010;28(12):2024\u201331. https:\/\/doi.org\/10.1200\/JCO.2009.23.8451.","journal-title":"J Clin Oncol"},{"issue":"25","key":"13476_CR8","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1200\/JCO.2010.31.4930","volume":"29","author":"M Untch","year":"2011","unstructured":"Untch M, Fasching PA, Konecny GE, Hasmuller S, Lebeau A, Kreienberg R, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol. 2011;29(25):3351\u20137. https:\/\/doi.org\/10.1200\/JCO.2010.31.4930.","journal-title":"J Clin Oncol"},{"issue":"9816","key":"13476_CR9","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0140-6736(11)61847-3","volume":"379","author":"J Baselga","year":"2012","unstructured":"Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012;379(9816):633\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(11)61847-3.","journal-title":"Lancet"},{"issue":"1","key":"13476_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25\u201332. https:\/\/doi.org\/10.1016\/S1470-2045(11)70336-9.","journal-title":"Lancet Oncol"},{"issue":"12","key":"13476_CR11","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(18)30570-9","volume":"19","author":"MS van Ramshorst","year":"2018","unstructured":"van Ramshorst MS, van der Voort A, van Werkhoven ED, Mandjes IA, Kemper I, Dezentje VO, et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(12):1630\u201340. https:\/\/doi.org\/10.1016\/S1470-2045(18)30570-9.","journal-title":"Lancet Oncol"},{"key":"13476_CR12","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.critrevonc.2017.02.014","volume":"112","author":"MA Lindenberg","year":"2017","unstructured":"Lindenberg MA, Miquel-Cases A, Retel VP, Sonke GS, Wesseling J, Stokkel MPM, et al. Imaging performance in guiding response to neoadjuvant therapy according to breast cancer subtypes: a systematic literature review. Crit Rev Oncol Hematol. 2017;112:198\u2013207. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.02.014.","journal-title":"Crit Rev Oncol Hematol"},{"key":"13476_CR13","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2020.4103","author":"MK Tasoulis","year":"2020","unstructured":"Tasoulis MK, Lee HB, Yang W, Pope R, Krishnamurthy S, Kim SY, et al. Accuracy of post-neoadjuvant chemotherapy image-guided breast biopsy to predict residual Cancer. JAMA Surg. 2020. https:\/\/doi.org\/10.1001\/jamasurg.2020.4103.","journal-title":"JAMA Surg"},{"key":"13476_CR14","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-09273-0","author":"AA van Loevezijn","year":"2020","unstructured":"van Loevezijn AA, van der Noordaa MEM, van Werkhoven ED, Loo CE, Winter-Warnars GAO, Wiersma T, et al. Minimally invasive complete response assessment of the breast after neoadjuvant systemic therapy for early breast cancer (MICRA trial): interim analysis of a multicenter observational cohort study. Ann Surg Oncol. 2020. https:\/\/doi.org\/10.1245\/s10434-020-09273-0.","journal-title":"Ann Surg Oncol"},{"key":"13476_CR15","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000004246","author":"J Heil","year":"2020","unstructured":"Heil J, Pfob A, Sinn HP, Rauch G, Bach P, Thomas B, et al. Diagnosing pathologic complete response in the breast after neoadjuvant systemic treatment of breast cancer patients by minimal invasive biopsy: oral presentation at the san antonio breast cancer symposium on friday, December 13, 2019, Program Number GS5-03. Ann Surg. 2020. https:\/\/doi.org\/10.1097\/SLA.0000000000004246.","journal-title":"Ann Surg"},{"key":"13476_CR16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1158\/1538-7445.SABCS19-GS5-05","volume":"80","author":"MCR Basik","year":"2020","unstructured":"Basik MCR, Santos JFDL, et al. Abstract GS5-05: Primary analysis of NRG-BR005, a phase II trial assessing accuracy of tumor bed biopsies in predicting pathologic complete response (pCR) in patients with clinical\/radiological complete response after neoadjuvant chemotherapy (NCT) to explore the feasibility of breast-conserving treatment without surgery. Cancer Res. 2020;80:5.","journal-title":"Cancer Res"},{"issue":"1","key":"13476_CR17","doi-asserted-by":"publisher","first-page":"e2034045","DOI":"10.1001\/jamanetworkopen.2020.34045","volume":"4","author":"EJ Sutton","year":"2021","unstructured":"Sutton EJ, Braunstein LZ, El-Tamer MB, Brogi E, Hughes M, Bryce Y, et al. Accuracy of magnetic resonance imaging-guided biopsy to verify breast cancer pathologic complete response after neoadjuvant chemotherapy: a nonrandomized controlled trial. JAMA Netw Open. 2021;4(1):e2034045. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.34045.","journal-title":"JAMA Netw Open"},{"issue":"22","key":"13476_CR18","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147\u201359. https:\/\/doi.org\/10.1056\/NEJMoa1612645.","journal-title":"N Engl J Med"},{"issue":"7","key":"13476_CR19","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive her2-positive breast cancer. N Engl J Med. 2019;380(7):617\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1814017.","journal-title":"N Engl J Med"},{"issue":"2","key":"13476_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"key":"13476_CR21","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.breast.2018.04.015","volume":"40","author":"MEM van der Noordaa","year":"2018","unstructured":"van der Noordaa MEM, van Duijnhoven FH, Loo CE, van Werkhoven E, van de Vijver KK, Wiersma T, et al. Identifying pathologic complete response of the breast after neoadjuvant systemic therapy with ultrasound guided biopsy to eventually omit surgery: study design and feasibility of the MICRA trial (Minimally Invasive Complete Response Assessment). Breast. 2018;40:76\u201381. https:\/\/doi.org\/10.1016\/j.breast.2018.04.015.","journal-title":"Breast"},{"issue":"5","key":"13476_CR22","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/jnci\/djs528","volume":"105","author":"ML Marinovich","year":"2013","unstructured":"Marinovich ML, Houssami N, Macaskill P, Sardanelli F, Irwig L, Mamounas EP, et al. Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. J Natl Cancer Inst. 2013;105(5):321\u201333. https:\/\/doi.org\/10.1093\/jnci\/djs528.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"13476_CR23","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.2214\/AJR.17.18323","volume":"210","author":"JR Scheel","year":"2018","unstructured":"Scheel JR, Kim E, Partridge SC, Lehman CD, Rosen MA, Bernreuter WK, et al. MRI, clinical examination, and mammography for preoperative assessment of residual disease and pathologic complete response after neoadjuvant chemotherapy for breast cancer: ACRIN 6657 Trial. AJR Am J Roentgenol. 2018;210(6):1376\u201385. https:\/\/doi.org\/10.2214\/AJR.17.18323.","journal-title":"AJR Am J Roentgenol"},{"key":"13476_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2020.09.014","author":"A Chan","year":"2021","unstructured":"Chan A, Moy B, Mansi J, Ejlertsen B, Holmes FA, Chia S, et al. Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial. Clin Breast Cancer. 2021. https:\/\/doi.org\/10.1016\/j.clbc.2020.09.014.","journal-title":"Clin Breast Cancer"},{"key":"13476_CR25","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS20-OT-03-01","author":"CE Geyer Jr","year":"2021","unstructured":"Geyer CE Jr, Untch M, Prat A, Rastogi P, Niikura N, Mathias E, Mclean LE, Wang Y, Loibl S. 2021) Abstract OT-03-01: Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: A randomized, phase 3 trial (DESTINY-Breast05. Cancer Res. 2021. https:\/\/doi.org\/10.1158\/1538-7445.SABCS20-OT-03-01.","journal-title":"Cancer Res"},{"key":"13476_CR26","doi-asserted-by":"publisher","first-page":"102459","DOI":"10.1016\/j.ctrv.2022.102459","volume":"110","author":"RC Bonadio","year":"2022","unstructured":"Bonadio RC, Tarantino P, Testa L, Punie K, Pernas S, Barrios C, et al. Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: what are the evidences? Cancer Treat Rev. 2022;110:102459.","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"13476_CR27","doi-asserted-by":"publisher","first-page":"e204103","DOI":"10.1001\/jamasurg.2020.4103","volume":"155","author":"MK Tasoulis","year":"2020","unstructured":"Tasoulis MK, Lee HB, Yang W, Pope R, Krishnamurthy S, Kim SY, et al. Accuracy of post-neoadjuvant chemotherapy image-guided breast biopsy to predict residual cancer. JAMA Surg. 2020;155(12):e204103.","journal-title":"JAMA Surg"},{"key":"13476_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00613-1","author":"HM Kuerer","year":"2022","unstructured":"Kuerer HM, Smith BD, Krishnamurthy S, Yang WT, Valero V, Shen Y, et al. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2022. https:\/\/doi.org\/10.1016\/S1470-2045(22)00613-1.","journal-title":"Lancet Oncol"},{"issue":"3","key":"13476_CR29","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S1470-2045(14)71221-5","volume":"16","author":"IH Kunkler","year":"2015","unstructured":"Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM, investigators PI. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 2015;16(3):266\u201373. https:\/\/doi.org\/10.1016\/S1470-2045(14)71221-5.","journal-title":"Lancet Oncol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-13476-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-023-13476-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-13476-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T20:24:48Z","timestamp":1688502288000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-023-13476-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,18]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["13476"],"URL":"https:\/\/doi.org\/10.1245\/s10434-023-13476-6","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,18]]},"assertion":[{"value":"28 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Annemiek K.E. van Hemert, Frederieke H. van Duijnhoven, Ariane A. van Loevezijn, Claudette E. Loo, Terry Wiersma, Emilie J. Groen, and Marie-Jeanne T.F.D. Vrancken Peeters declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}